Objective: The present study aims to investigate the underlying mechanisms accounting for the activities of everolimus to inhibit the growth of vascular smooth muscle cells (VSMCs), which contributes to restenosis. Methods: Primary VSMCs were cultured in media containing smooth muscle growth supplements and incubated with testing agents. Cell proliferation, cell cycle distribution, apoptosis and autophagy, and the key molecules involved, were examined. Results: Everolimus inhibited the proliferation of VSMCs by inhibiting the activation of ribosomal protein S6 kinase and phosphorylation of eukaryotic translation initiation factor 4E-binding protein 1, and downregulating proliferating cellular nuclear antigen. Everolimus induced cell cycle arrest at the G1 phase by downregulating cyclin D1 and upregulating p27, and increased apoptosis by downregulating Bcl-2, upregulating Bad and activating capsase-3 and poly ADP ribose polymerase. Everolimus enhanced autophagy by increasing the conversion of microtubule-associated protein 1 light chain 3 (LC3)-I to LC3-II, and upregulating Beclin 1. Specific autophagy inhibitors, 3-methyladenine and bafilomycin A1, significantly attenuated the inhibition of cell proliferation, the increased apoptosis and the altered expression of the above key proteins induced by everolimus. Conclusions: Enhanced autophagy by everolimus contributes to its antirestenotic activity and its abilities to inhibit cell proliferation and to induce apoptosis of VSMCs.

1.
Seedial SM, Ghosh S, Saunders RS, Suwanabol PA, Shi X, Liu B, Kent KC: Local drug delivery to prevent restenosis. J Vasc Surg 2013;57:1403-1414.
2.
Dzau VJ, Braun-Dellaeus RC, Shedding DG: Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 2002;8:1249-1256.
3.
Hamon M, Lecluse E, Monassier JP, Grollier G, Potier JC: Pharmacological approaches to the prevention of restenosis after coronary angioplasty. Drugs Aging 1998;13:291-301.
4.
Lavigne MC, Grimsby JL, Eppihimer MJ: Antirestenotic mechanisms of everolimus on human coronary artery smooth muscle cells: inhibition of human coronary artery smooth muscle cell proliferation, but not migration. J Cardiovasc Pharmacol 2012;59:165-174.
5.
Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P: Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-948.
6.
Patel JK, Kobashigawa JA: Everolimus: an immunosuppressive agent in transplantation. Expert Opin Pharmacother 2006;7:1347-1355.
7.
Carter AJ, Brodeur A, Collingwood R, Ross S, Gibson L, Wang CA, Haller S, Coleman L, Virmani R: Experimental efficacy of an everolimus eluting cobalt chromium stent. Catheter Cardiovasc Interv 2006;68:97-103.
8.
Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ; SPIRIT IV Investigators: Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362:1663-1674.
9.
Lammer J, Bosiers M, Zeller T, Schillinger M, Boone E, Zaugg MJ, Verta P, Peng L, Gao X, Schwartz LB: First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg 2011;54:394-401.
10.
Ferri N, Granata A, Pirola C, Torti F, Pfister PJ, Dorent R, Corsini A: Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression. Mol Pharmacol 2008;74:144-153.
11.
Lebwohl D, Anak O, Sahmoud T, Klimovsky J, Elmroth I, Haas T, Posluszny J, Saletan S, Berg W: Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann NY Acad Sci 2013;1291:14-32.
12.
Parry TJ, Brosius R, Thyagarajan R, Carter D, Argentieri D, Falotico R, Siekierka J: Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol 2005;524:19-29.
13.
Wessely R, Blaich B, Belaiba RS, Merl S, Görlach A, Kastrati A, Schömig A: Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Thromb Haemost 2007;97:1003-1012.
14.
Li W, Li Q, Qin L, Ali R, Qyang Y, Tassabehji M, Pober BR, Sessa WC, Giordano FJ, Tellides G: Rapamycin inhibits smooth muscle cell proliferation and obstructive arteriopathy attributable to elastin deficiency. Arterioscler Thromb Vasc Biol 2013;33:1028-1035.
15.
Carrera AC: mTOR signaling in mammals. J Cell Sci 2004;117:4615-4616.
16.
Sini P, James D, Chresta C, Guichard S: Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells. Autophagy 2010;6:553-554.
17.
Su M, Mei Y, Sinha S: Role of the crosstalk between autophagy and apoptosis in cancer. J Oncol 2013;2013:102735.
18.
Rikiishi H: Novel insights into the interplay between apoptosis and autophagy. Int J Cell Biol 2012;2012:317645.
19.
Wang D, Ma Y, Li Z, Kang K, Sun X, Pan S, Liu L, Liang D, Jiang H: The role of AKT1 and autophagy in the protective effect of hydrogen sulphide against hepatic ischemia/reperfusion injury in mice. Autophagy 2012;8:954-962.
20.
Wei Z, Jiang X, Qiao H, Zhai B, Zhang L, Zhang Q, Wu Y, Jiang H, Sun X: STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells. Cell Signal 2013;25:931-938.
21.
Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J: mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004;24:200-216.
22.
Braun-Dullaeus RC, Mann MJ, Seay U, Zhang L, von Der Leyen HE, Morris RE, Dzau VJ: Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol 2001;21:1152-1158.
23.
Fukumoto S, Koyama H, Hosoi M, Yamakawa K, Tanaka S, Morii H, Nishizawa Y: Distinct role of cAMP and cGMP in the cell cycle control of vascular smooth muscle cells. Circ Res 1999;85:985-991.
24.
Larrea MD, Wander SA, Slingerland JM: p27 as Jekyll and Hyde: regulation of cell cycle and cell motility. Cell Cycle 2009;8:3455-3461.
25.
Tai S, Sun Y, Liu N, Ding B, Hsia E, Bhuta S, Thor RK, Damoiseaux R, Liang C, Huang J: Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells. Mol Cancer Ther 2012;11:1320-1331.
26.
Bergmann A: Survival signaling goes BAD. Dev Cell 2002;3:607-608.
27.
Willis S, Day CL, Hinds MG, Huang DC: The Bcl-2-regulated apoptotic pathway. J Cell Sci 2003;116:4053-4056.
28.
Chiarugi A, Moskowitz MA: PARP-1 - a perpetrator of apoptotic cell death. Science 2002;297:259-263.
29.
Shintani T, Klionsky DJ: Autophagy in health and diease: a double-edged sword. Science 2004;306:990-995.
30.
Codogno P, Mehrpour M, Proikas-Cezanne T: Canonical and non-canonical autophagy: variations on a common theme of self-eating? Nat Rev Mol Cell Biol 2012;13:7-12.
31.
Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Packer M, Mizushima N, Packer M, Schneider MD, Levine B: Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005;122:927-939.
32.
Smith DM, Patel S, Raffoul F, Haller E, Mills GB, Nanjundan M: Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells. Cell Death Differ 2010;17:1867-1881.
33.
Tanida I, Ueno T, Kominami E: LC3 and autophagy. Methods Mol Biol 2008;445:77-88.
34.
Salabei JK, Hill BG: Implications of autophagy for vascular smooth muscle cell function and plasticity. Free Radic Biol Med 2013;65:693-703.
35.
Salabei JK, Cummins TD, Singh M, Jones SP, Bhatnagar A, Hill BG: PDGF-mediated autophagy regulates vascular smooth muscle cell phenotype and resistance to oxidative stress. Biochem J 2013;451:375-388.
36.
Nishida Y, Arakawa S, Fujitani K, Yamaguchi H, Mizuta T, Kanaseki T, Komatsu M, Otsu K, Tsujimoto Y, Shimizu S: Discovery of Atg5/Atg7-independent alternative macroautophagy. Nature 2009;461:654-658.
37.
Funderburk SF, Wang QJ, Yue Z: The Beclin 1-VPS34 complex - at the crossroads of autophagy and beyond. Trends Cell Biol 2010;20:355-362.
38.
Petiot A, Ogier-Denis E, Blommaart EFC, Meijer AJ, Codogno P: Distinct classes of phosphatidylinositol 30 kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J Biol Chem 2000;275:992-998.
39.
Moreau K, Ravikumar B, Puri C, Rubinsztein DC: Arf6 promotes autophagosome formation via effects on phosphatidylinositol 4,5-bisphosphate and phospholipase D. J Cell Biol 2012;196:483-496.
40.
Rosich L, Colomer D, Roue G: Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma. Autophagy 2013;9:115-117.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.